# Ardelyx (ARDX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ARDX
## Company Profile
- Ticker: ARDX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 3.97 USD
- Market cap: 1363602216.24 USD
- Last updated: 2026-08-12
## Business Overview
### NHE3 Inhibition Platform
Ardelyx develops and commercializes medicines based on inhibition of the sodium-hydrogen exchanger 3 in the gastrointestinal tract. Its approach changes intestinal sodium transport and can affect bowel function and phosphate absorption.
### IBSRELA and XPHOZAH
IBSRELA is approved for irritable bowel syndrome with constipation, while XPHOZAH is approved to lower serum phosphorus in adults with chronic kidney disease on dialysis who have an inadequate response or intolerance to phosphate binders. Both products contain tenapanor.
### Pipeline Expansion
The Phase 3 ACCEL trial is evaluating IBSRELA in adults with chronic idiopathic constipation. RDX10531 is a next-generation NHE3 inhibitor being explored across additional therapeutic applications.
## Why The Stock Is Moving

As of Aug 12, 2026, ARDX closed up 0.76% at $3.97. No new same-company headline was identified in the current news window.

## Future Catalysts

- Completion of enrollment in the Phase 3 ACCEL trial expected by year-end 2026.
- Topline ACCEL results expected in the second half of 2027.

## Recent News
- 2026-08-06 20:05 EST — [Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/ARDX/ardelyx-reports-second-quarter-2026-financial-results-and-provides-business-upda-6ff72f66) — Source: Ardelyx
- 2026-07-23 12:01 EST — [Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026](https://biopharmsignal.com/news/ARDX/ardelyx-to-report-second-quarter-2026-financial-results-on-august-6-2026-cf11d40a) — Source: Ardelyx
- 2026-05-19 12:01 EST — [Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026](https://biopharmsignal.com/news/ARDX/ardelyx-to-participate-at-the-jefferies-global-healthcare-conference-2026-a45950e8) — Source: Ardelyx
- 2026-05-07 12:01 EST — [Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings](https://biopharmsignal.com/news/ARDX/ardelyx-presents-analysis-supporting-long-term-safety-of-xphozah-at-nkf-s-spring-06ad1b71) — Source: Ardelyx
- 2026-04-30 20:01 EST — [Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/ARDX/ardelyx-reports-first-quarter-2026-financial-results-and-provides-business-updat-8ab879af) — Source: Ardelyx